

# HEMISPHERX BIOPHARMA SELECTED BY MSN MONEY CENTRAL'S STOCKSCOUTER AS ONE OF HIGHEST RATED SMALL-CAP BIOTECHS

Release: 7/24/2001

**Philadelphia, PA, Tuesday, July 24, 2001:** Hemispherx Biopharma, Inc. (AMEX: HEB), a leading biopharmaceutical company specializing in the development of nucleic acids to enhance anti-viral defense systems in the human body, announced today that it was selected by MSN Money Central Investor's "StockScouter" rating system as one of the top 10 highest rated small-cap biotech companies.

The complete article, in which Hemispherx is listed, can be viewed at:  
<https://www.moneycentral.msn.com/articles/invest/speculator/7048.asp?special=msn>

About MSN Money Central's StockScouter

MSN Money Central, [www.moneycentral.msn.com](http://www.moneycentral.msn.com), built the StockScouter rating system to help individual investors quickly analyze and assess a stock's potential for outperforming the broad market. Working closely with Camelback Research Alliance, an independent research firm at the cutting edge of financial engineering for institutional money managers, StockScouter identifies statistically predictive traits that affect the performance of successful U.S. securities, and develops a systematic way to provide investor research. For more information on StockScouter and its rating system, please visit <https://moneycentral.msn.com/articles/invest/extra/7102.asp>.

About Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Philadelphia, PA, has devoted nearly three decades to exploring, understanding, and mastering the mechanism of ribonucleic acid (RNA) drug technology. The Company's lead drug product, Ampligen®, is currently in Phase III clinical trials for the treatment of Chronic Fatigue Syndrome and Phase IIb clinical trials for the treatment of HIV. The Company's longevity as a biomedical research and drug development institution, coupled with its record of enduring scientific achievement, is evidence of long-term commitment to these promising new classes of drugs for the chronically ill and to bring new therapeutic choices to the global health care community. For more information, please visit the company's website at [www.hemispherx.net](http://www.hemispherx.net).

You may register to receive Hemispherx Biopharma's future press releases or to download a complete Digital Investor Kit™ including press releases, regulatory filings and corporate materials by clicking on the "Digital Investor Kit™" icon at [www.kcsa.com](http://www.kcsa.com).

Information contained in this news release other than historical information, should all be considered forward-looking and are subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.